_esmo-e-learning-parp-inhibitors-past-present-and-future.jpg "ESMO E-Learning: PARP Inhibitors: Past, Present and Future from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 44 min 74 sec
✓ Published: 14-Oct-2021
✓ Published: 14-Oct-2021
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_wicked-fart.webp "Muesli maketh the man.")
_parp-serwis.webp "CreditsnCLIENT: PARPnAGENCY: Scholz & FriendsnPRODUCTION: Dorota SieradzkanANIMATION DIRECTOR: Michal Socha, BrosFXnCREATION: Agnieszka Niska- Wojcik, BrosFXnREALIZATION: BrosFX: Directing, Concept Design, Animation, Postproduction")
_e4-sting-2007.webp "My submission to the E4 stings competition 2007.")
_parp-inhibitor-monotherapy.webp "In this GU CONNECT programme, brought to you by Dr Neal Shore, you’ll follow a patient through their metastatic castration-resistant prostate cancer (mCRPC) journey and explore the clinical implementation of genetic testing and monotherapy treatment with a PARPi.nnWatch the 5-minute animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testing and how to use it to assess HRRm status and")
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.webp "β-Nicotinamide Mononucleotide (1094-61-7) Manufacturer - Coftteknnhttps://www.cofttek.com/product/1094-61-7/nnβ-Nicotinamide Mononucleotide (NMN) SpecificationsnnnnName:nβ-Nicotinamide Mononucleotide (NMN)nnnCAS:n1094-61-7nnnPurityn98%nnnMolecular Formula:nC11H15N2O8PnnnMolecular Weight:n334.2208 g/molnnnMelt Point:n96°CnnnChemical name:n((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphatennnSynonyms:nNicotinamide Mononucleotide; NMN;")
_how-do-genetic-mutations-impact-prostate-cancer-treatment-options.webp "How do genetic mutations impact prostate cancer treatment options? Dr. Himisha Beltran shares how information about genetic mutations play into treatment decisions and discusses the role of PARP inhibitor therapies and immunotherapies.nnDr. Himisha Beltran is Director of Translational Research in the Department of Medical Oncology at Dana-Farber Cancer Institute. Learn more about Dr. Beltran, here: https://www.dana-farber.org/find-a-doctor/himisha-beltran/.")
_technics-su-9070-test.webp "parp")
_our-resilient-genome.webp "Our Resilient Genome is a short science animation that tells the story of our DNA, how it is constantly breaking and rebuilding over and over again to keep us alive, and provides a glimpse into the fascinating world of cellular biology.nnThis work has been carried out within the PhysioIllustration project and is funded by NFR (project #218023)nThe Bergen University Fund (Universitetsfondet)nBEK/ Bergen senter for elektronisk kunst bek.nonnContributors and Scientific Advisors:nAnne-Kristin Stavru")
_wicked-fart.jpg)
_parp-serwis.jpg)
_e4-sting-2007.jpg)
_parp-inhibitor-monotherapy.jpg)
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.jpg)
_how-do-genetic-mutations-impact-prostate-cancer-treatment-options.jpg)
_technics-su-9070-test.jpg)
_our-resilient-genome.jpg)
![[+]](/images/menu.gif){kind=small}